Do analysts recommend PRTC or BDTX?

Black Diamond Therapeutics has a consensus price target of $10.25, indicating a potential upside of 460.11%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Black Diamond Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64

Which has stronger valuation & earnings, PRTC or BDTX?

Black Diamond Therapeutics has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Black Diamond Therapeutics $70M 1.50 $22.37M -$0.75 N/A

Is PRTC or BDTX more profitable?

PureTech Health's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PureTech Health N/A N/A N/A Black Diamond Therapeutics N/A -32.10% -25.21%

Does the media prefer PRTC or BDTX?

In the previous week, Black Diamond Therapeutics had 5 more articles in the media than PureTech Health. MarketBeat recorded 6 mentions for Black Diamond Therapeutics and 1 mentions for PureTech Health. Black Diamond Therapeutics' average media sentiment score of 0.92 beat PureTech Health's score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Black Diamond Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MYGN or BDTX?

In the previous week, Myriad Genetics and Myriad Genetics both had 6 articles in the media. Black Diamond Therapeutics' average media sentiment score of 0.92 beat Myriad Genetics' score of 0.51 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Diamond Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AVTE or BDTX?

Black Diamond Therapeutics has a consensus target price of $10.25, indicating a potential upside of 460.11%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Black Diamond Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64

Is AVTE or BDTX more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Black Diamond Therapeutics N/A -32.10% -25.21%

Is ZURA or BDTX more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -56.13% -50.15% Black Diamond Therapeutics N/A -32.10% -25.21%

Does the media refer more to ZURA or BDTX?

In the previous week, Black Diamond Therapeutics had 2 more articles in the media than Zura Bio. MarketBeat recorded 6 mentions for Black Diamond Therapeutics and 4 mentions for Zura Bio. Black Diamond Therapeutics' average media sentiment score of 0.92 beat Zura Bio's score of 0.17 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Black Diamond Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BDTX or EDIT?

In the previous week, Editas Medicine had 9 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 15 mentions for Editas Medicine and 6 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.92 beat Editas Medicine's score of 0.55 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Black Diamond Therapeutics (BDTX) Competitors

$1.83 +0.02 (+1.10%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.83 0.00 (-0.05%)

As of 10/9/2026 07:30 PM Eastern

Compare

BDTX vs. PRTC, MYGN, AVTE, ZURA, and EDIT

Should you buy Black Diamond Therapeutics stock or one of its competitors? Black Diamond Therapeutics's main competitors and comparable companies include PureTech Health (PRTC), Myriad Genetics (MYGN), Aerovate Therapeutics (AVTE), Zura Bio (ZURA), and Editas Medicine (EDIT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Black Diamond Therapeutics compare to PureTech Health?

PureTech Health (NASDAQ:PRTC) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Black Diamond Therapeutics has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Black Diamond Therapeutics	$70M	1.50	$22.37M	-$0.75	N/A

Black Diamond Therapeutics has a consensus price target of $10.25, indicating a potential upside of 460.11%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

PureTech Health has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.32, meaning that its stock price is 232% more volatile than the broader market.

In the previous week, Black Diamond Therapeutics had 5 more articles in the media than PureTech Health. MarketBeat recorded 6 mentions for Black Diamond Therapeutics and 1 mentions for PureTech Health. Black Diamond Therapeutics' average media sentiment score of 0.92 beat PureTech Health's score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Black Diamond Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PureTech Health's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Black Diamond Therapeutics beats PureTech Health on 10 of the 13 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Myriad Genetics?

Myriad Genetics (NASDAQ:MYGN) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Black Diamond Therapeutics has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$806.60M	0.51	-$365.90M	-$1.19	N/A
Black Diamond Therapeutics	$70M	1.50	$22.37M	-$0.75	N/A

Myriad Genetics currently has a consensus price target of $3.93, indicating a potential downside of 8.74%. Black Diamond Therapeutics has a consensus price target of $10.25, indicating a potential upside of 460.11%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Black Diamond Therapeutics has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

In the previous week, Myriad Genetics and Myriad Genetics both had 6 articles in the media. Black Diamond Therapeutics' average media sentiment score of 0.92 beat Myriad Genetics' score of 0.51 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Diamond Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Myriad Genetics has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.32, indicating that its share price is 232% more volatile than the broader market.

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 1.9% of Myriad Genetics shares are held by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Black Diamond Therapeutics beats Myriad Genetics on 11 of the 15 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Black Diamond Therapeutics' return on equity of -32.10% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

In the previous week, Black Diamond Therapeutics had 6 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 6 mentions for Black Diamond Therapeutics and 0 mentions for Aerovate Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.92 beat Aerovate Therapeutics' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Black Diamond Therapeutics	Positive

Black Diamond Therapeutics has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Black Diamond Therapeutics	$70M	1.50	$22.37M	-$0.75	N/A

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.32, indicating that its share price is 232% more volatile than the broader market.

Black Diamond Therapeutics has a consensus target price of $10.25, indicating a potential upside of 460.11%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Black Diamond Therapeutics beats Aerovate Therapeutics on 13 of the 14 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Zura Bio?

Zura Bio (NASDAQ:ZURA) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 12.4% of Zura Bio shares are owned by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Black Diamond Therapeutics had 2 more articles in the media than Zura Bio. MarketBeat recorded 6 mentions for Black Diamond Therapeutics and 4 mentions for Zura Bio. Black Diamond Therapeutics' average media sentiment score of 0.92 beat Zura Bio's score of 0.17 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Black Diamond Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Black Diamond Therapeutics' return on equity of -32.10% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-56.13%	-50.15%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

Black Diamond Therapeutics has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A
Black Diamond Therapeutics	$70M	1.50	$22.37M	-$0.75	N/A

Zura Bio has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.32, suggesting that its stock price is 232% more volatile than the broader market.

Zura Bio currently has a consensus price target of $17.00, indicating a potential upside of 325.00%. Black Diamond Therapeutics has a consensus price target of $10.25, indicating a potential upside of 460.11%. Given Black Diamond Therapeutics' higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Black Diamond Therapeutics beats Zura Bio on 12 of the 15 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Editas Medicine?

Black Diamond Therapeutics (NASDAQ:BDTX) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Black Diamond Therapeutics has a net margin of 0.00% compared to Editas Medicine's net margin of -157.32%. Black Diamond Therapeutics' return on equity of -32.10% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Editas Medicine	-157.32%	-196.63%	-38.17%

In the previous week, Editas Medicine had 9 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 15 mentions for Editas Medicine and 6 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.92 beat Editas Medicine's score of 0.55 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Black Diamond Therapeutics has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.50	$22.37M	-$0.75	N/A
Editas Medicine	$40.52M	10.99	-$160.06M	-$0.75	N/A

Black Diamond Therapeutics has a beta of 3.32, suggesting that its share price is 232% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by insiders. Comparatively, 3.1% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Black Diamond Therapeutics currently has a consensus price target of $10.25, suggesting a potential upside of 460.11%. Editas Medicine has a consensus price target of $5.83, suggesting a potential upside of 101.15%. Given Black Diamond Therapeutics' higher probable upside, equities research analysts plainly believe Black Diamond Therapeutics is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Black Diamond Therapeutics beats Editas Medicine on 12 of the 15 factors compared between the two stocks.

Get Black Diamond Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDTX vs. The Competition

Export

Metric	Black Diamond Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$103.99M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-2.44	13.42	274.15	26.16
Price / Sales	1.50	1,234.38	635.98	112.53
Price / Cash	3.43	116.56	76.38	53.09
Price / Book	0.93	17.17	11.21	6.34
Net Income	$22.37M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-3.17%	-1.33%	-0.90%	-1.41%
1 Month Performance	-6.63%	-8.44%	-4.44%	-3.48%
1 Year Performance	-55.26%	14.02%	6.96%	1.16%

Black Diamond Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDTX Black Diamond Therapeutics	3.7232 of 5 stars	$1.83 +1.1%	$10.25 +460.1%	-57.6%	$103.99M	$70M	N/A	21	News Coverage Positive News
PRTC PureTech Health	0.0065 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100	News Coverage Positive News
MYGN Myriad Genetics	1.7559 of 5 stars	$4.34 +6.8%	$3.93 -9.3%	-44.3%	$414.64M	$824.50M	N/A	2,700	News Coverage Gap Up
AVTE Aerovate Therapeutics	N/A	$13.77 -2.0%	N/A	+55.8%	$399.12M	N/A	N/A	20	High Trading Volume
ZURA Zura Bio	2.6107 of 5 stars	$4.17 +0.6%	$17.00 +308.2%	-11.3%	$397.22M	N/A	N/A	40	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDTX) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Black Diamond Therapeutics (BDTX) Competitors

BDTX vs. PRTC, MYGN, AVTE, ZURA, and EDIT

How does Black Diamond Therapeutics compare to PureTech Health?

Summary

How does Black Diamond Therapeutics compare to Myriad Genetics?

Summary

How does Black Diamond Therapeutics compare to Aerovate Therapeutics?

Summary

How does Black Diamond Therapeutics compare to Zura Bio?

Summary

How does Black Diamond Therapeutics compare to Editas Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX vs. The Competition

Black Diamond Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Black Diamond Therapeutics (BDTX) Competitors

BDTX vs. PRTC, MYGN, AVTE, ZURA, and EDIT

How does Black Diamond Therapeutics compare to PureTech Health?

Which has stronger valuation & earnings, PRTC or BDTX?

Do analysts recommend PRTC or BDTX?

Which has more volatility & risk, PRTC or BDTX?

Does the media prefer PRTC or BDTX?

Is PRTC or BDTX more profitable?

Do institutionals and insiders believe in PRTC or BDTX?

Summary

How does Black Diamond Therapeutics compare to Myriad Genetics?

Which has better valuation and earnings, MYGN or BDTX?

Do analysts prefer MYGN or BDTX?

Is MYGN or BDTX more profitable?

Does the media refer more to MYGN or BDTX?

Which has more risk & volatility, MYGN or BDTX?

Do insiders & institutionals believe in MYGN or BDTX?

Summary

How does Black Diamond Therapeutics compare to Aerovate Therapeutics?

Is AVTE or BDTX more profitable?

Does the media favor AVTE or BDTX?

Which has preferable earnings and valuation, AVTE or BDTX?

Do insiders & institutionals believe in AVTE or BDTX?

Which has more volatility & risk, AVTE or BDTX?

Do analysts recommend AVTE or BDTX?

Summary

How does Black Diamond Therapeutics compare to Zura Bio?

Do institutionals and insiders believe in ZURA or BDTX?

Does the media refer more to ZURA or BDTX?

Is ZURA or BDTX more profitable?

Which has preferable earnings & valuation, ZURA or BDTX?

Which has more risk & volatility, ZURA or BDTX?

Do analysts recommend ZURA or BDTX?

Summary

How does Black Diamond Therapeutics compare to Editas Medicine?

Is BDTX or EDIT more profitable?

Does the media prefer BDTX or EDIT?

Which has better earnings & valuation, BDTX or EDIT?

Which has more volatility & risk, BDTX or EDIT?

Do insiders & institutionals believe in BDTX or EDIT?

Do analysts recommend BDTX or EDIT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX vs. The Competition

Black Diamond Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools